Telomerase reverse transcriptase promoter mutations in hepatocellular carcinogenesis  

作　　者：Zi-Xian Ma Chun-Mei Yang Meng-Ge Li Hong Tu 

机构地区：[1]State Key Laboratory of Oncogenes and Related Genes,Shanghai Cancer Institute,Renji Hospital,Shanghai Jiao Tong UniversitySchool of Medicine,Shanghai 200032,China

出　　处：《Hepatoma Research》2019年第3期8-19,共12页肝癌研究（英文版）

基　　金：This work was supported by grants from the National Natural Science Foundation of China(81572312);Chinese National Key Project Specialized for Infectious Diseases(2017ZX10201201-008-003);National Key Research and Development Program of China(2017YFC0908103);Chinese State Key Laboratory of Oncogenes and Related Genes(91-14-16,91-15-06).

摘　　要：Through several studies exploiting next-generation sequencing,we are obtaining a clearer picture of the complex genetic and molecular landscape of hepatocellular carcinoma(HCC).Consistent with the findings of other cancer types,telomerase reverse transcriptase(TERT)promoter mutations have been frequently reported in HCC.C228T and C250T are two major types of hot spot mutations in the TERT promoter region.Besides,in hepatitis B virus(HBV)-related HCC cases,the TERT promoter is recurrently interrupted by integration of HBV DNA.TERT promoter mutations are thought to be an early event in HCC carcinogenesis,and they are significantly associated with disease progression.In this review,we provide an updated overview of the somatic mutations in the TERT promoter region and discuss their possible roles in the development of HCC.

关 键 词：Hepatocellular carcinoma telomerase reverse transcriptase mutation hepatitis B virus 

分 类 号：R73[医药卫生—肿瘤]